AstraZeneca, Korea’s Hanmi Move To Appellate Court In Nexium Patent Dispute
This article was originally published in PharmAsia News
Executive Summary
A recent settlement agreement at the U.S. district court level does little to resolve a battle over AstraZeneca’s second best-selling drug. Saying its position is on “solid ground,” it remains unclear if Hanmi would pursue an at-risk launch if it receives final FDA approval.